CARSON CITY, Nev., Oct. 23, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), («BioVie” or the „Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share, resulting in total gross proceeds of $6,000,750, before deducting the placement agent's fees and offering expenses.